All/Science/A Thorough QT Study of Teduglutide in Healthy Subjects.Redaktion CRS . 20. April 2020Teduglutide, an analog of the endogenous hormone glucagon-like peptide-2, is currently being developed for the treatment of short bowel syndrome. read moregastrointestinalpeptidespharmacodynamicspharmacokineticsQTc intervalOnce-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.Editor Client . 20. April 2020Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. I read moreSequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.Editor Client . 20. April 2020We investigated the effect of sequential treatment escalation with dapagliflozin and saxagliptin on beta cell function in patients with T2DM insufficiently controlled on metformin monotherapy during a hyperglycaemic clamp investigation. read morebeta cell functionDPP-IV inhibitionhyperglycaemic clampSGLT-2 inhibitionHypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.Prof. Dr. Thomas Forst . 19. März 2020Basal insulin peglispro (BIL) has a peripheral-to-hepatic distribution of action that resembles endogenous insulin and a prolonged duration of action with a flat pharmacokinetic/pharmacodynamic profile at steady … read morediabetesdosing accuracyinjection paininsulin pensubcutaneous injectionAccuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial.Prof. Dr. Thomas Forst . 19. März 2020First published in Journal Diabetes care on 2017 JanDiabetes Care. 2017 Jan;40(1):63-68. doi: 10.2337/dc16-1525. Epub 2016 Nov 4 Authors: Kropff J, Choudhary P, Neupane S, Barnard K, Bain SC, Kapitza C, Forst T, Link M, Dehennis A, DeVries JH Abstract Objective: It is known that continuous glucose monitoring (CGM) systems can lower mean glucose compared… read morediabetesdosing accuracyinsulin penEndoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: Indications and clinical relevance in a single investigator cohort of 47 patients.Prof. Dr. Thomas Forst . 18. März 2020First published in Endocrine. 2017 Apr/ Endocrine. 2017 Apr56(1):158-163. doi: 10.1007/s12020-016-1179-z. Epub 2016 Nov 30 Authors: Kann PH, Moll R, Bartsch D, Pfützner A, Forst T, Tamagno G, Goebel JN, Fourkiotis V, Bergmann SR, Collienne M Abstract Purpose. This study was aimed to investigate the role and relevance of endoscopic ultrasound-guided fine-needle aspiration biopsy in… read moreEndoscopic ultrasound (EUS)Fine-needle aspiration biopsy (FNA)InsulinomaNeuroendocrine tumor (NET)PancreasEffects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.Prof. Dr. Thomas Forst . 18. März 2020First published in John Wiley & Sons Ltd., Diabetes obesity and metabolism on 2017 Apr.Diabetes Obes Metab. 2017 Apr;19(4):489-495. doi: 10.1111/dom.12838. Epub 2017 Jan 10 Authors: Forst T, Falk A, Andersen G, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L Abstract Aims To investigate the effect of sequential treatment escalation with… read moreDPP‐4 inhibitionSGLT‐2 inhibitionα‐cell functionβ‐cell functionImpact of Injection Speed, Volume, and Site on Pain SensationProf. Dr. Thomas Forst . 18. März 2020First published in Journal of Diabetes Science and Technology on 2018 JanJ Diabetes Sci Technol. 2018 Jan;12(1):163-168. doi: 10.1177/1932296817735121. Epub 2017 Oct 8 Authors: Zijlstra E, Jahnke J, Fischer A, Kapitza C, Forst T Abstract Background: Painful subcutaneous insulin injections may decrease treatment compliance. Improving injection comfort therefore represents a particular area of technological research… read morediabetesdosing accuracyinjection paininsulin pensubcutaneous injectionAcceptability of Implantable Continuous Glucose Monitoring SensorProf. Dr. Thomas Forst . 18. März 2020First published in Journal of Diabetes Science and Technology on 2018 MayJ Diabetes Sci Technol. 2018 Jan;12(1):163-168. doi: 10.1177/1932296817735121. Epub 2017 Oct 8 Authors: Barnard KD, Kropff J, Choudhary P, Neupane S, Bain SC, Kapitza C, Forst T, Link M, Mdingi C, DeVries JH Abstract Background: Real-time continuous glucose monitoring is associated with significant benefits… read morecontinuous glucose monitoringimplantablepsychosocialtype 1 diabetesCardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleasedProf. Dr. Thomas Forst . 18. August 2017First published in Der Internist on 2017 MarsInternist (Berl). 2017 Mar;58(3):293-302. doi: 10.1007/s00108-017-0189-0. Review. German Authors:Forst T, Plum-Mörschel L, Weber MM Abstract Cardiovascular disease significantly determines morbidity and mortality in patients with diabetes mellitus type 2. Large clinical trials in the past left controversial evidence about the effect of blood glucose-lowering treatments on cardiovascular outcomes.… read moreagonistsDiabetes mellitus type 2Dipeptidyl peptidase 4 proteinGlucagon-like peptide-1 receptorinhibitorsSodium-glucose transporter 2 CRO Leadership Awards 2019 CRS is proud to be recognised again by pharma companies worldwide as a leading CRO with regard to: capabilities, compatibility, quality and reliability. European Biotechnology Guide Find CRS’s company profile in the European Biotechnology Science Industry Guide, volume 9 2019. EcoVadis – CSR Rating Based on the CSR rating by EcoVadis in July 2018 CRS has been granted Silver Recognition Level.